Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in Five ASEAN Countries
This agreement conclusion will lead to an expansion into Southeast Asia of an agreement regarding dotinurad in China concluded by Eisai and FUJI YAKUHIN in February 2020.
- This agreement conclusion will lead to an expansion into Southeast Asia of an agreement regarding dotinurad in China concluded by Eisai and FUJI YAKUHIN in February 2020.
- Based on this agreement, Eisai will acquire exclusive development and marketing rights for dotinurad in the said five countries from FUJI YAKUHIN.
- FUJI YAKUHIN will retain responsibility for manufacturing the formulation of dotinurad, and supply to Eisai.
- Eisai will be responsible for New Drug Applications for dotinurad in the said five countries and pay FUJI YAKUHIN an upfront payment and sales milestones.